Press Release - Piramal Pharma Solutions ("PPS") and NewAmsterdam Pharma invest indedicated suite to enhance Oral Solid Dosage capabilities at PPS' Sellersville, Pennsylvania site

Capex & Operations View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹192.50

prior close

₹192.50

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.2%+0.3% vs market

Pharmaceuticals peers, median of 151sector-0.1%+0.2% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Smallcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.6

15m

+0.5

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1-0.2+0.3-0.1+0.2

Next day

+0.0-0.1+0.1-0.5+0.5

-1.5-2.0+0.4-1.6+0.1

-3.3-3.0-0.3-2.7-0.6

-4.8-3.3-1.5-2.8-2.0

-2.3-2.0-0.3-1.6-0.7

+4.4-0.6+4.9-1.0+5.3

15d

+6.0+1.0+4.9-0.4+6.3

+5.4+1.6+3.8-0.0+5.4

+5.6+1.0+4.6-2.8+8.4

-3.0-2.7-0.3-6.2+3.2

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma Solutions (PPS), the CDMO arm of Piramal Pharma, along with NewAmsterdam Pharma, has opened a dedicated oral solid dosage (OSD) manufacturing suite at the Sellersville, Pennsylvania facility. The suite is built through a multi-million-dollar investment in equipment upgrades and reconfiguration of existing space to produce a fixed-dose combination (FDC) of NewAmsterdam's investigational cholesterol drug obicetrapib with ezetimibe. The Sellersville site will handle commercial production, while Piramal's Ahmedabad site supported development and Pithampur provides dual sourcing. The investment is expected to create over 20 new jobs at Sellersville over the next five years and strengthens PPS's position as an integrated CDMO partner for global pharma clients.

Likely market impact

This is a positive operational update for shareholders, signaling PPS's growing role as a preferred CDMO partner and expected incremental revenue from NewAmsterdam's FDC if the drug is approved. The investment size is described only as 'multi-million-dollar' with no specific figure, so the financial impact is limited at this stage.